Available review articles discuss the potential role of ampicillin sulbactam in treating different infections. A 2002 review article assessed the clinical efficacy of ampicillin/sulbactam in managing severe pediatric infections, highlighting its effectiveness in treating brain abscesses in children. In a study of 21 patients, including those with multiple lesions, treatment at 100/50 mg/kg per day for an average of 48 days was successful, with three deaths unrelated to the infection or therapy (Table 1). Another evaluation of 57 pediatric cases, ranging from 2 months to 16 years old, reported similar outcomes. The findings reinforced ampicillin/sulbactam as a potent empiric therapy for a broad range of pediatric infections, particularly in settings with high beta-lactamase-producing pathogen prevalence. [1], [2]
In general, ampicillin and sulbactam reach high concentration in cerebrospinal fluid (CSF), surpassing the minimum inhibitory concentration (MIC) of key bacterial pathogens. Standard dosing of sulbactam, given as 2 g of ampicillin with 1 g of sulbactam every six hours, has been considered sufficient for crossing the blood-brain barrier though effectiveness may vary based on the extent of meningeal inflammation and the pathogen’s susceptibility. [1], [2]
A 2024 systematic literature review identified 47 eligible reports, encompassing 67 cases of Actinomyces turicensis infections. Most infections involved the anogenital region (31%) or presented as abscess-forming diseases, with concurrent bacteremia observed in 10% of cases. Polymicrobial infection was common, with A. turicensis frequently co-isolated with anaerobes. Empirical treatment strategies varied, though beta-lactams, particularly amoxicillin-clavulanate, were the most frequently used agents; use of ampicillin/sulbactam occurred in 6 cases, though combinations with other antimicrobials and durations of therapy varied. Surgical intervention, including debridement or drainage, was required in 76% of cases. Despite diagnostic challenges, 89% of patients achieved full recovery, while two fatal cases were documented. One case study involving an adult male with a brain abscess caused by A. turicensis is reported in Table 2. [3]
A 1986 pharmacokinetic study characterized the penetration of sulbactam and ampicillin into body fluids and tissues, demonstrating that both compounds extensively diffused into blister fluid, peritoneal fluid, and sputum. While cerebrospinal fluid penetration was generally poor in the absence of inflammation, meningitis facilitated a significant increase in drug concentrations, with sulbactam levels in cerebrospinal fluid reaching up to 32% of serum levels; one patient with a brain abscess had a 9% serum sulbactam level in cerebrospinal fluid. However, discussion on penetration in the presence of specific microorganisms was not discussed. [4]